System Maintenance Alert

ACC.org and related websites will be offline for maintenance Wednesday, Nov. 4 at 7 p.m. until 11 p.m. ET. Your patience is appreciated as we work to enhance our systems.

ACCEL Lite: SINGLE-AF: Anticoagulation For AFib With Intermediate Stroke Risk

Nov 03, 2026   |  Dhanunjaya R. Lakkireddy, MBBS, FACC; Boyoung Joung, MD

Podcast
Print
Font Size
A
A
A

The SINGLE-AF study evaluated whether direct oral anticoagulant (DOAC) therapy improves outcomes in patients with atrial fibrillation (AFib) who are at intermediate risk of stroke. The primary goal was to determine the net clinical benefit of anticoagulation compared with no anticoagulant therapy. The findings support the use of DOACs in appropriately selected patients with intermediate stroke risk.

In this episode, Dhanunjaya Lakkireddy MBBS, FACC and Boyoung Joung, MD discuss SINGLE-AF: Anticoagulation for atrial fibrillation with intermediate stroke risk.

Related References:

  1. Fauchier L, Clementy N, Bisson A, et al. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?. Stroke. 2016;47(7):1831-1836. doi:10.1161/STROKEAHA.116.013253
  2. Lip GY, Skjøth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65(14):1385-1394. doi:10.1016/j.jacc.2015.01.04421
  3. Østergaard L, Olesen JB, Petersen JK, et al. Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA2DS2-VASc Score 1: A Nationwide Study. Circulation. 2024;149(10):764-773. doi:10.1161/CIRCULATIONAHA.123.066477
Subscribe to the ACCEL Lite Podcast

Clinical Topics: Arrhythmias and Clinical EP, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias

Keywords: ACCELLite, ESC26, Electrophysiology